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Abstract: Primary aldosteronism is a disease of excessive production of adrenal steroid hormones and
the most common cause of endocrine hypertension. Primary aldosteronism results mainly from bilateral
adrenal hyperplasia or unilateral aldosterone-producing adenoma (APA). Primary aldosteronism cause
at the molecular level is incompletely understood and a targeted treatment preventing excessive adrenal
steroid production is not available. Here, we perform deep quantitative proteomic and phosphoproteomic
profiling of 6 pairs of APA and adjacent nontumoral adrenal cortex. We show that increased steroidoge-
nesis in APA is accompanied by upregulation of steroidogenic enzymes (HSD3B2, CYP21A2, CYP11B2)
and of proteins involved in cholesterol uptake (LSR). We demonstrate that HSD3B2 is phosphorylated at
Ser95 or 96 and identify a novel phosphorylation site, Ser489, in CYP21A2, suggesting that steroidogenic
enzymes are regulated by phosphorylation. Our analysis also reveals altered ECM (extracellular matrix)
composition in APA that affects ECM-cell surface interactions and actin cytoskeleton rearrangements.
We show that RHOC, a GTPase controlling actin organization in response to extracellular stimuli, is
upregulated in APA and promotes expression of the aldosterone synthase gene CYP11B2. Our data also
indicate deregulation of protein N-glycosylation and GABAergic signaling in APAs. Finally, we find that
mTORC1 (mammalian target of rapamycin complex 1) signaling is the major pathway deregulated in
APA. Our study provides a rich resource for future research on the molecular mechanisms of primary
aldosteronism.
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Primary aldosteronism (PA) is the most common form of endocrine hypertension, affecting 6% of the general hy-
pertensive population and 11% of patients in specialized hy-
pertension referral centers.1 PA most commonly results from 
bilateral adrenal hyperplasia (BAH) and unilateral aldosterone-
producing adenoma (APA), which together account for >95% 
of PA cases.2 Independent of hypertension, PA is associated 
with an increased risk of hypokalemia, cardiovascular and 
metabolic complications, renal impairment, osteoporosis, de-
pression, and anxiety.3,4 These conditions are attributable to el-
evated production of aldosterone, glucocorticoids, and adrenal 
androgens.3 Current PA treatment includes adrenalectomy for 
APA patients and mineralocorticoid receptor antagonists for 
BAH, as well as APA patients who are not eligible for surgery.2 
Pharmacological inhibition of mineralocorticoid receptors nor-
malizes blood pressure and hypokalemia but does not address 
metabolic complications and osteoporosis.4 Thus, additional 
therapeutic strategies are needed.
Approximately 50% of APAs harbor somatic mutations in 
genes encoding ion channels or pumps (KCNJ5, CACNA1D, 
ATP1A1, ATP2B3) that regulate intracellular ion homeostasis 
and cell membrane potential.5 Other molecular events lead-
ing to PA development are still incompletely understood. 
Transcriptome profiling has identified genes with a potential 
role in APA pathophysiology.5 However, biological processes 
are driven by proteins and transcript levels often do not pre-
dict protein amounts.6 Mass spectrometry allows proteomic 
analysis including the identification of posttranslational mod-
ification in an unbiased, quantitative, and sensitive manner.6 
Here, we use this powerful method to profile the proteome and 
phosphoproteome of APA and matched nontumoral adrenal 
cortex. In addition to confirming disturbances characterized 
in previous studies, we identify novel pathways potentially in-
volved in APA development and its hormonal autonomy. Our 
observations provide insight into APA pathophysiology that 
may translate into novel PA treatments.
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Methods
The authors declare that all supporting data are available within the 
article and its online-only Data Supplement.
Subjects
Adrenal tissue was collected from patients undergoing adrenalec-
tomy for APA at the University Hospital Munich. PA/APA diagnosis 
was in accordance with institutional guidelines. Postoperative histo-
logical examination confirmed APA in all patients except patient 3 
in which 3 distinct (6,7, and 10 mm) macronodules were identified. 
It was not determined whether the macronodules were because of 
nodular hyperplasia or were 3 independent adenomas. For all molec-
ular analyses of patient 3, only material from the dominant 10 mm 
nodule was taken. Given the histopathologic findings, all tumoral 
samples are hereafter referred to as APAs or adenomas. In all sam-
ples, APA-associated genes (KCNJ5, ATP1A1, ATP2B3, CACNA1D, 
CACNA1H, CTNNB1) and PRKACA were sequenced, as described in 
another study.7 Sequencing results and patients’ clinical characteris-
tics are provided in Table S1 in the online-only Data Supplement. All 
patients provided written informed consent. The study was approved 
by the Ethics Committee of the Ludwig-Maximilian University of 
Munich.
For detailed description of materials and methods see Materials 
and Methods in the online-only Data Supplement.
Results
Quantitative Proteomics and Phosphoproteomics of 
APA
We compared the proteomes and phosphoproteomes, here-
after collectively referred to as (phospho)proteomes, of 6 
pairs of APA and matched nontumoral adrenal cortex (Ctrl) 
(Figure 1A). The matched nontumoral tissue contained cells 
of all 3 zones of the adrenal cortex. On average, our deep 
quantitative mass spectrometry quantified around 7000 pro-
teins per patient, of which 12% to 28% were deregulated in 
APAs (Figure 1B). Proteins were considered deregulated 
when they were differentially expressed by >0.585 log2 fold 
(>1.5-fold; P<0.05) or they were detected exclusively in Ctrl 
or APA samples. We detected and quantified 5555 proteins 
common to all samples, of which 18 were significantly down-
regulated and 11 were significantly upregulated in all APAs 
(Figure 1B; Tables S4 and S5). Depending on the amount 
of the input material, we quantified between 1036 and 4075 
phosphosites per patient, which corresponded to 724–1969 
phosphoproteins (Figure 1C and 1D; Table S2). Up to 50% of 
quantified phosphoproteins had at least 1 phosphosite that was 
significantly deregulated in APA (Figure 1D). We were able to 
quantify 870 specific phosphosites in 785 phosphoproteins in 
at least 4 patients, but there was no phosphosite common to all 
samples (Figure 1C and 1D).
Steroidogenesis in APA Is Deregulated at Many 
Levels
Steroid hormones are synthesized from cholesterol in a series 
of reactions catalyzed by mitochondria- and ER-associated 
enzymes (Figure 2A). We found that in addition to an ex-
pected increase in aldosterone synthase (CYP11B2) expres-
sion, APAs showed higher levels of HSD3B2 and CYP21A2, 
the enzymes common to all steroid synthesis pathways 
(Figure 2A and 2B; Figure S1). Levels of enzymes specifi-
cally involved in glucocorticoid and androgen synthesis were 
either not affected (CYP17A1, CYP11B1) or only modestly 
downregulated (AKR1C3) in APAs (Figure 2B; Figure S1). 
Expression of STAR, a protein controlling cholesterol trans-
port across the inner mitochondrial membrane, was not 
changed in APAs (Figure 2B; Figure S1). The increase in 
expression of steroidogenic enzymes observed in the APA 
samples most likely contributes to the higher aldosterone 
synthesis characteristic of PA. The enhanced expression of 
HSD3B2 and CYP21A2 could account for increased levels 
of circulating glucocorticoids and androgens as observed in a 
significant portion of PA patients.
Previous studies have reported differential expression of 
steroidogenic enzymes in APAs harboring the KCNJ5 muta-
tion (hereafter referred to as KCNJ5mut).8–10 We observed lower 
levels of glucocorticoid and androgen producing enzymes 
(CYP11B1, CYP17A1, AKR1C3) in KCNJ5mut compared 
with KCNJ5WT adenomas, while aldosterone synthase levels 
showed the opposite trend (Figure S2). CYP11A1, HSD3B2, 
and CYP21A2 were unchanged (Figure S2). Furthermore, 
expression of steroidogenic enzymes was comparable in all 
control tissues (Figure S2). Our observed changes in expres-
sion of CYP11B2/B1/17 are consistent with that reported in 
previous transcriptomic studies.9,10 However, they differ from 
those reported in an immunohistochemistry study which 
showed lower expression of CYP11B2 and higher expression 
of CYP17A1 in KCNJ5mut adenomas.8 Whether this apparent 
discrepancy is because of experimental differences or other 
factors is unknown.
Steroidogenic output is influenced not only by the abso-
lute levels of steroidogenic enzymes but also by their specific 
activity. It is known that the activity of STAR and CYP17A1 
is regulated by a cAMP-dependent phosphorylation of 
Ser19511 and an undetermined Ser/Thr site,12 respectively. 
STAR phosphorylation was not affected in APAs (Figure 
S3), suggesting that this modification does not contribute to 
increased steroid hormone production. However, our phos-
phoproteomic analysis identified 2 new phosphorylation sites 
in other steroidogenic enzymes, Ser95 or 96 (Ser95/96) in 
HSD3B2 and Ser489 in CYP21A2. HSD3B2-pSer95/96, a 
predicted PKA target (www.cbs.dtu.dk/services/NetPhos), 
was quantified and found to be deregulated in 3 APAs (Figure 
2C). CYP21A2-pSer489, predicted to be phosphorylated 
by GSK3 and other unspecified kinases, was quantified in 2 
APAs and found to be upregulated in 1 (Figure 2C). These 
observations suggest that protein kinases regulate steroido-
genic enzyme activity.
Oxidation reactions catalyzed by mitochondrial steroido-
genic enzymes require FDX1 and FDXR for electron transfer, 
whereas steroidogenic enzymes of the ER require POR and 
CYB5. APAs displayed a decrease in FDX1 and CYB5A ex-
pression and normal FDXR and POR levels (Figure 2D; Figure 
S1). Thus, elevated steroidogenic output in APA seems not to 
be driven by increased electron transfer. It is not clear whether 
decreased FDX1 and CYB5A levels could negatively impact 
steroidogenic output and thereby constitute a mechanism to 
counter increased expression of steroidogenic enzymes. This 
requires further study.
Excessive steroidogenesis requires increased cholesterol 
supply. This can be achieved by upregulating either de novo 
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lipid droplets, or lipoprotein uptake.13 De novo choles-
terol synthesis most likely does not contribute to increased 
steroidogenesis since neither of the quantified enzymes 
involved in this pathway was upregulated in APAs 
(Figure 2E). Mobilization of cholesterol from lipid droplets 
is also an unlikely contributor—HSL (an enzyme mobiliz-
ing cholesterol from lipid droplets) and SOAT1 (an enzyme 
modulating lipid droplets assembly) were downregulated 
and upregulated, respectively, in APAs (Figure 2E; Figure 
S1). Surprisingly, canonical lipoprotein receptors were ei-
ther unchanged (VLDLR, LDLR, SR-B1) or downregu-
lated (CD36) in APAs (Figure 2E; Figure S1). Likewise, 
proteins mobilizing lipoprotein-derived cholesterol were 
not changed (NPC1 [Niemann-Pick C1], LIPA) or showed 
only a modest increase (NPC2; Figure 2E; Figure S1). 
Among the lipoprotein receptors, lipolysis-stimulated li-
poprotein receptor (LSR), which binds VLDL and LDL, 
was upregulated in adenomas (Figure 2E; Figure S1). Thus, 
it can be speculated that cholesterol required to support 
increased steroidogenesis in APAs comes from LDL and is 
taken up via LSR.
Clusters of Downregulated and Upregulated 
Proteins in APA
To visualize the variance of the proteomic data, we performed 
principal component analysis (PCA) of proteins detected in 
all mass spectrometry runs of all patient (5077 proteins in 
total). This analysis revealed that adenoma proteomes differ 
from those of control adrenal cortex (Figure 3A). In addi-
tion, PCA showed that APA samples harboring KCNJ5mut are 
distinct from those with the wild-type version of the channel 
(Figure 3A). Interestingly, also Ctrl samples corresponding 
to KCNJ5mut adenomas clustered and were clearly separated 
from other control samples (Figure 3A). This may suggest that 
Figure 1. Experimental setup for deep quantitative aldosterone-producing adenoma (APA) (phospho)proteomics. A, Schematic overview of the study. B, 
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KCNJ5mut affects not only the tumor but the whole gland, for 
example, by promoting secretion of a paracrine factor or by 
inducing a systemic response affecting other adrenocortical 
cells. In summary, PCA demonstrates that APAs share many 
characteristics at the proteome level and clearly differ from 
the surrounding nontumoral adrenal cortex, irrespective of 
their genetic background.
To identify proteins with a similar expression pattern 
across all APAs, we performed unsupervised hierarchical 
clustering of proteins that were quantified in all samples and 
Figure 2. Steroidogenesis in aldosterone-producing adenoma (APA) is deregulated at multiple levels. A, Overview of adrenal steroidogenic pathways. 
(mt): mitochondria-associated enzymes, (ER): ER-associated enzymes. B, Expression of steroidogenic enzymes in APA. C, Quantification of HSD3B2 
and CYP11B2 phosphorylation on newly discovered sites. D, Expression of enzymes involved in electron transport to the steroidogenic enzymes in 
APA. E, Expression of proteins involved in cholesterol synthesis and trafficking in APA. ND: Not detected. NC: Not changed. B–E, Data are presented as 
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significantly deregulated in at least 2 adenomas (3210 proteins 
in total). Clustering was based on the normalized expression 
data (Z scores). Column-wise clustering confirmed the PCA 
results, demonstrating that APA proteomes differ from those 
of the Ctrl adrenal cortex, and that samples from patients har-
boring KCNJ5mut cluster (Figure 3B). Row-wise clustering 
Figure 3. Proteomic analysis reveals proteins differentially regulated in aldosterone-producing adenoma (APA). A, Principal component analysis of proteins 
detected in each mass spectrometry measurement of all the samples. * denotes patients harboring KCNJ5mut. B, Unsupervised hierarchical clustering of 
proteins quantified in all samples and deregulated in at least 2 adenomas. C and D, KEGG pathway enrichment for proteins of (C) APALOW and (D) APAHIGH 
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revealed the presence of 2 prominent clusters of proteins with 
a similar expression pattern in APAs (Figure 3B). These clus-
ters, termed APALOW and APAHIGH, contain proteins downregu-
lated and upregulated in APA, respectively (Tables S6 and S7).
We performed KEGG and Reactome pathway enrichment 
analyses of proteins within the APALOW and APAHIGH clusters. 
The APALOW cluster was particularly enriched in pathway 
terms related to ECM (extracellular matrix) homeostasis and 
ECM-cell interactions (Figure 3C; Figure S4). In contrast, the 
APAHIGH cluster was particularly enriched in pathway terms 
related to protein N-linked glycosylation and amino acid me-
tabolism (Figure 3D; Figure S4). Consistent with the charac-
teristics of adenomas, the APAHIGH cluster was also enriched in 
proteins involved in steroidogenesis (Figure S4).
To validate the results of the Z score-based hierarchical 
clustering, we manually searched for proteins significantly 
dowregulated or upregulated in at least 4 APAs (Tables S8 and 
S9) and performed pathway enrichment analyses of these 2 
protein groups. Consistent with previous results, commonly 
downregulated proteins corresponded to pathways involved in 
ECM homeostasis and ECM-receptor interactions (Figure 3E; 
Figure S5), while upregulated proteins corresponded to amino 
acid metabolism and steroidogenesis (Figure 3F; Figure S5). 
In addition, commonly upregulated proteins were linked to 
calcium signaling (Figure 3F; Figure S5).
PCA and unsupervised hierarchical clustering suggested 
that KCNJ5mut APAs are more similar to each other than to 
KCNJ5WT adenomas. This prompted us to search manually for 
proteins whose expression is altered in all 3 KCNJ5mut APAs. 
Out of 142 proteins commonly downregulated in KCNJ5mut 
tumors, 57 showed reduced expression exclusively in the 
KCNJ5mut cohort while 85 were also downregulated in at least 
one KCNJ5WT adenoma (Tables S10 and S11). Likewise, 89 
of 173 proteins commonly upregulated in KCNJ5mut tumors 
showed higher expression only in these tumors (Tables S12 
and S13). Pathway enrichment analyses revealed that proteins 
downregulated specifically in KCNJ5mut APAs are involved 
mainly in xenobiotic metabolism, whereas the upregulated 
proteins are involved in ion transport across plasma mem-
brane and iron homeostasis (Figure S6). These findings imply 
that, while sharing many characteristics with the KCNJ5WT 
tumors, KCNJ5mut adenomas display a distinct protein expres-
sion pattern.
To complement our study, we performed pathway en-
richment analyses of proteins downregulated or upregulated 
in APAs of individual patients and created a ranking of com-
monly deregulated pathways among all patients. This analysis 
confirmed that pathways commonly downregulated in APAs 
were related to maintaining ECM homeostasis and ECM-
cell interactions, whereas the commonly upregulated path-
ways corresponded to N-glycosylation and calcium signaling 
(Figure S7). In addition, this analysis identified oxidative 
phosphorylation to be commonly upregulated in adenomas 
(Figure S7).
APA Is Characterized by Disturbed ECM-Cell 
Surface-Cytoskeleton Interactions
All the above analyses indicate downregulation of path-
ways related to the ECM and ECM-cell interactions in APA 
(Figure 4A). Most adenomas showed significantly lower con-
tent (>1.5-fold, P<0.05) of various collagen types (COL1A1-
2, COL6A1-3, COL14A1), proteins mediating collagen fibril 
assembly (COL14A1, FMOD, LUM, BGN, DCN, PCOLCE, 
ASPN), other ECM structural components (EFEMP2, 
PRELP, DPT, LAMC3), and enzymes involved in ECM turn-
over (PCOLCE, CMA1, TPSAB1). Likewise, expression of 
ITG7A (integrin α-7), which provides the link between the 
ECM and intracellular signaling, was downregulated in all 
adenomas tested (Table S4). The actin cytoskeleton, which 
regulates various cellular processes in response to the extra-
cellular signals,14 also appeared to be affected in APA—a few 
cytoskeleton-associated proteins (MYLK, FLNC) displayed 
reduced expression in adenomas compared with the matched 
adrenal cortex. In contrast, RHOC, a GTPase activated in re-
sponse to extracellular stimuli and controlling formation and 
organization of the actin cytoskeleton,15 was upregulated in 
all APAs (Table S5). Thus, APAs showed disturbed ECM-cell 
interactions at all possible levels: ECM composition, cell sur-
face receptor expression, and actin cytoskeleton rearrange-
ments (Figure 4A).
Protein N-Linked Glycosylation Is Increased in APA
Pathway enrichment analyses of proteins with increased ex-
pression in APAs indicated that N-linked glycosylation is 
upregulated in adenomas. N-glycosylation entails transfer of 
preassembled oligosaccharide from dolichol phosphate to an 
asparagine residue in a process catalyzed by a heterooligo-
meric enzyme oligosaccharyltransferase (OST)16(Figure 4B). 
Multiple enzymes involved in the oligosaccharide assembly 
were significantly (P<0.05) upregulated >1.5-fold in 3 
(ALG2, ALG6, ALG14) or 2 (ALG1, ALG11) adenomas. In 
addition, APAs displayed increased content of the OST com-
plex components when compared with the corresponding 
control adrenal cortex. In particular, RNP1, RNP2, DDOST, 
STT3A, and MAGT1 were significantly upregulated at least 
1.45-fold in 3 adenomas, and expression of DAD1 and OSTC 
was significantly increased >1.5-fold in 2 APAs. Finally, 
TUSC3, an accessory component of the OST complex, was 
> 2-fold upregulated in 4 APAs. Adenomas also displayed 
higher content of enzymes participating in formation of com-
plex N-glycans, including MGAT2 (>1.5-fold increase in 3 
adenomas) and MGAT1 and MAN1A2 (>1.5-fold increase 
in 2 APAs). In summary, APAs showed increased expres-
sion of enzymes involved in N-glycan assembly and thereby 
most likely higher rates of protein N-linked glycosylation 
(Figure 4B). Of note, N-linked glycosylation was one of the 
top upregulated pathways in patients 1 through 4 (Figure S5) 
and was therefore not related to the KCNJ5 status.
GABA Degradation Is Enhanced in APA
In the performed KEGG pathway enrichment analyses, pro-
teins upregulated in APA corresponded to pathways related 
to amino acid (KEGG terms Alanine, aspartate and gluta-
mate metabolism and Arginine and proline metabolism) and 
butanoate metabolism (Figure 3D and 3F; Figures S4 and 
S5). Most proteins we detected linked to these terms are in-
volved in various independent pathways. Only 2 are involved 
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an inhibitory neurotransmitter, is metabolized to succinate 
by the serial action of 2 enzymes, ABAT and ALDH5A1.17 
ABAT was significantly upregulated 1.58- to 4.20-fold in all 
6 APAs compared with their corresponding controls (Table 
S5). ALDH5A1 levels were >1.5-fold higher in 3 adeno-
mas and 1.28-fold higher in 1 adenoma. This observation 
Figure 4. Proteomic analysis identifies novel aldosterone-producing adenoma (APA) associated pathways. A, APAs displayed changes in expression of 
various ECM (extracellular matrix) components, Integrin α-7, and proteins involved in actin cytoskeleton organization. B, APAs showed increased levels of 
multiple proteins involved in N-linked glycosylation. Proteins downregulated in APAs are boxed in blue while upregulated proteins are boxed in red. Proteins 































476  Hypertension  February 2019
raises the possibility that APAs have reduced inhibitory 
GABAergic signaling.
Validation of the Proteomic Data
To validate the proteomics results, we examined 4 selected 
candidate proteins with differential expression in APA and 
nontumoral adrenal cortex by immunoblotting. We probed 
APA and Ctrl adrenal cortex protein lysates with antibodies 
against 3 members (RHOC, HX1, LSR) of the APAHIGH cluster 
and 1 member (HSL) of the APALOW cluster. Immunoblot anal-
ysis confirmed the proteomic results for all proteins. RHOC, 
HX1, and LSR displayed overall higher expression in APAs, 
while HSL showed lower expression (Figure 5A and 5B). This 
validation by immunoblotting indicates the reliability of the 
presented proteomic data.
RHOC Regulates Expression of CYP11B2 in 
Cultured Cells
The GTPase RHOC was upregulated in all tested adenomas 
(Table S5; Figure 5A and 5B). To understand the functional 
implications of this finding, we transiently transfected human 
adrenocortical NCI-H295R cells with a plasmid encoding 
RHOC (Figure 5C) and assessed proliferation and CYP11B1 
and CYP11B2 mRNA levels. While RHOC overexpression 
did not affect cell proliferation (Figure 5D) or expression 
of CYP11B1 (Figure 5E), it significantly increased expres-
sion of the gene encoding aldosterone synthase CYP11B2 
(Figure 5E). Thus, RHOC is a potential novel regulator of al-
dosterone synthesis. This observation also suggests that our 
approach allows identification of novel proteins involved in 
APA pathophysiology.
mTORC1 (Mammalian Target of Rapamycin 
Complex 1) Signaling Is Increased in APA
Phosphorylation regulates protein activity in numerous bio-
logical pathways. To assess which pathways are most affected 
by changes in phosphorylation in APA, we performed KEGG 
pathway enrichment analysis of phosphoproteins that had at 
least one significantly deregulated phosphorylation site in 
>50% of APA samples. This analysis identified mTOR (mam-
malian target of rapamycin) signaling to be the most deregu-
lated pathway in adenomas (Figure 6A), and pointed toward 
deregulation of actin cytoskeleton rearrangements, mRNA 
metabolism, and protein chaperones (Figure 6A). mTOR is a 
serine/threonine kinase that forms 2 structurally and function-
ally distinct multiprotein complexes, mTORC1 (mTOR com-
plex 1) and mTORC2 (mTOR complex 2).18 Detailed analysis 
of proteins enriched under the KEGG term mTOR signaling 
suggested deregulation of mTORC1 rather than mTORC2 
signaling. To confirm this, we probed APA and Ctrl adrenal 
cortex protein lysates for S6-pSer240/244 and Akt-pSer473, 
the well-established markers of mTORC1 and mTORC2 
activity, respectively. S6-pSer240/244 expression was sig-
nificantly increased in APAs compared with the respective 
Figure 5. Validation of the proteomic data and identification of new proteins potentially involved in aldosterone-producing adenoma (APA) pathophysiology. 
A, Immunoblot validation of differential expression of selected proteins in APA and Ctrl adrenal cortex samples. B, Quantification of immunoblot signals 
presented in A. Data are shown as means±SD. *P<0.05, **P<0.01 (paired t test). C, RHOC expression in NCI-H295R cells transiently transfected with RHOC-
encoding vector. D, Proliferation assay of NCI-H295R cells transiently overexpressing RHOC. E, Expression of CYP11B1 and CYP11B2 in NCI-H295R cells 
transiently overexpressing RHOC. C–E, Control (Ctrl) cells were transfected with an empty plasmid. Data are presented as means±SD. *P<0.05 (Wilcoxon 
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controls, while Akt-pSer473 expression was not changed 
(Figure 6B and 6C). Thus, mTORC1 but not mTORC2 signal-
ing seems to be increased in adenomas.
Kinase-Substrate Enrichment Analysis Reveals 
Kinases Deregulated in APA
To identify the top hypoactive and hyperactive kinases in 
APA, we performed kinase-substrate enrichment analysis. 
This method infers kinase activity by averaging the signals 
for multiple phosphosites targeted by a given kinase and is 
based on the analysis of curated substrate-kinase interactions 
deposited in public databases (Materials and Methods in the 
online-only Data Supplement). Of note, only 1 325 of 9 742 
phosphosites quantified in this study have predicted kinases. 
This suggests that less characterized kinases might have an 
important role in APAs. Kinase-substrate enrichment analysis 
indicated decreased activity of LIMK1/2, TESK1, MAPK1, 
and PAK1 and increased activity of AMPK, PAK2, AKT1, 
CHEK1, and MAPK1 kinases in APA (Figure 6D). The pres-
ence of MAPK1 in both lists suggests that its activity was 
decreased toward certain targets (eg, CTTN) and increased 
toward others (eg, SLC9A1). String analysis revealed that 
most of the top deregulated kinases functionally or physically 
interact (Figure 6E), suggesting that they cooperate within 
the same signaling pathway(s). To identify such pathways, 
we performed KEGG and Reactome pathway enrichments of 
the top deregulated kinases. In both analyses, the terms cor-
responding to cytoskeleton remodeling and axonal guidance 
appeared among the top 5 identified pathways (Figure 6F). 
Thus, both proteomic and phosphoproteomic data indicate 
Figure 6. Phosphoproteomic analysis reveals signaling pathways and kinases deregulated in aldosterone-producing adenoma (APA). A, KEGG pathway 
enrichment analysis of phosphoproteins deregulated in at least 4 adenomas. B, Immunoblot evaluating mTORC1 (mammalian target of rapamycin complex 1) 
and mTORC2 (mTOR complex 2) signaling in APAs. C, Quantification of western blot signals presented in B. Data are shown as mean±SD, *P<0.05 (paired t 
test). D, Top hypoactive and hyperactive kinases in APA identified in kinase-substrate enrichment analysis (KSEA). E, String analysis and (F) KEGG/Reactome 
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that development of APA is accompanied by changes in cyto-
skeleton and possibly innervation.
Discussion
Here we present the first APA (phospho)proteome using deep 
quantitative mass spectrometry. Our results reveal potentially 
novel molecular mechanisms in APA pathophysiology. First, 
the finding that HSD3B2 and CYP21A2 are phosphorylated 
in APA suggests that the activity of steroidogenic enzymes is 
regulated by phosphorylation. This is further supported by the 
large-scale phosphoproteomic studies (http://www.phospho-
siteplus.org) indicating that the major steroidogenic enzymes 
(CYP11A1, CYP21A2, CYP17A1, AKR1C3, CYP11B1, and 
CYP11B2) are phosphorylated at multiple sites. Since C17–20 
lyase activity of CYP17A1 is increased by phosphorylation,12 
it is possible that phosphorylation also modulates activity of 
other steroidogenic enzymes. Further studies on mechanisms 
and physiological relevance of steroidogenic enzyme phos-
phorylation are required.
Second, our observation that LSR is the only lipopro-
tein receptor upregulated in APA suggests that LSR mediates 
the uptake of cholesterol for steroidogenesis. However, LSR 
also has functions beyond lipoprotein uptake. LSR affects 
cell motility and invasion19 and expression of genes encoding 
actin, tight junction proteins, and proteins affecting cancer 
progression.19 Thus, increased expression of LSR in APA 
might not only provide cholesterol to support steroidogen-
esis but may also affect actin cytoskeleton dynamics and cell 
proliferation.
Third, our proteomic data suggest striking changes in 
ECM and actin cytoskeleton composition in APAs. It is well 
established, that binding of ECM proteins to their cognate 
receptors (integrins) on the cell surface initiates signaling 
cascades that control various cellular functions, including 
proliferation, differentiation, and migration.14 Many of these 
functions are regulated via RHO GTPases and lead to changes 
in actin cytoskeleton structure.15 It has also been shown that 
ECM composition has a profound effect on adrenocortical cell 
function. Signals from the extracellular environment are crit-
ical for fetal adrenal gland development, where they coordi-
nate steroid hormone production and cell turnover.20 Indeed, 
binding of fibronectin or collagens to cultured adrenocortical 
cells promotes steroidogenesis while laminins enhance prolif-
eration.21 ACTH (corticotropin) and Ang II (angiotensin II), 
the major regulators of steroidogenesis, exert their effect, at 
least in part, through promoting actin cytoskeleton rearrange-
ments.22,23 In addition, the RHOA-ROCK pathway, which acts 
downstream of ECM-integrin signaling, has been shown to 
differentially affect steroid hormone production by inhibit-
ing glucocorticoid synthesis and promoting androgen pro-
duction.24 Here, we demonstrate that RHOC, another member 
of the RHO GTPases family, specifically regulates CYP11B2 
expression, and presumably aldosterone production, without 
affecting CYP11B1 or cellular proliferation. Whether RHOC 
exerts this effect via regulating the actin cytoskeleton or by 
affecting other signaling pathways requires further research. 
Of note, mRNAs encoding various extracellular proteins are 
overexpressed in cortisol-producing adenomas,25 further high-
lighting the role of ECM in adrenal gland pathophysiology.
Fourth, our observation that APAs display increased 
expression of various protein involved in protein 
N-glycosylation suggests a role for N-glycosylation in APA 
pathophysiology. Clients of this posttranslational modifica-
tion include nearly all secreted and cell surface proteins, as 
well as many proteins residing in the ER, Golgi, or lyso-
somes. The modification promotes protein folding, stability, 
trafficking, localization and oligomerization, and affects 
cell-cell/ECM interactions, intracellular signaling, and cel-
lular metabolism.16,26 It is often deregulated in tumors, where 
it affects all steps of development and progression.26 The 
role of N-glycosylation in the adrenal cortex has not been 
studied in detail, although the modification is prominent in 
adrenocortical cells and has been postulated to affect local 
synthesis and quality control of membrane proteins involved 
in cholesterol and steroid metabolism.27 Key regulators of 
steroidogenesis, MC2R and AT1R (receptors for ACTH 
and Ang II, respectively), are N-glycosylated and their ac-
tivity could be affected by glycosylation. Similarly, lipopro-
tein receptors (LDLR and SR-B1) and many ion channels 
affecting steroidogenesis (TASK1, TASK3, TREK1, Kv1.4, 
CACNA1D) are N-glycoproteins and their levels/activities 
could be affected by increased glycosylation. This might be 
particularly true for the ion channels. Disruption of TASK1 
and TASK3 glycosylation lowers the number of cell surface 
channels, which leads to a reduced current flow.28 Similarly, 
inhibiting N-glycosylation of Kv1.4 channel decreases pro-
tein stability, induces intracellular retention, and decreases 
cell surface protein levels.29 Thus, enhanced N-glycosylation 
observed in APA may promote steroidogenesis via increas-
ing cell surface expression and activity of relevant receptors 
and ion channels.
Fifth, our finding that APAs exhibit increased expression 
of 2 enzymes involved in GABA degradation suggests that 
reduced GABAergic signaling leads to APA. This hypothesis 
is further supported by the results of our phosphoproteomic 
analysis implicating kinases normally involved in axonal 
guidance. Activation of GABAergic signaling decreases ste-
roidogenesis in the rat adrenal cortex in vivo,30 and GABA 
receptors are expressed on the surface of human adrenal cortex 
cells.31 Interestingly, adrenocortical cells themselves express 
GABA synthesis machinery.31 Benzodiazepines, which en-
hance GABA action via GABA
A
 receptor, inhibit steroid 
production by adrenocortical cells in vitro. Thus, it is likely 
that ABAT and ALDH5A1 overexpression in APA contrib-
utes to steroid hormone production by decreasing inhibitory 
GABAergic signaling. If this is the case, PA patients could 
benefit from treatment with GABA receptor agonists or ABAT 
inhibitors. Recently, it has been shown that ABAT controls the 
mitochondrial nucleoside salvage pathway, and its inhibition 
leads to decreased mitochondrial content.32 Thus, increased 
ABAT expression in APA could also contribute to maintain-
ing high mitochondrial count required to support enhanced 
steroidogenesis.
Last, our data indicate that mTORC1 signaling is the 
most deregulated pathway in APAs. This is consistent with 
previous histological studies showing that mTOR activity is 
commonly upregulated both in APA and BAH.33 mTORC1 































Swierczynska et al  APA Proteomic Landscape  479
APA cells and immortalized adrenocortical cells.33–35 Thus, 
increased mTORC1 signaling in APA could contribute to ad-
enoma growth and increased steroidogenic output. Whether 
inhibition of mTORC1 provides patients with clinical benefit 
requires further studies.
APAs display different morphologies and gene expres-
sion patterns that correlate with genetic makeup.36 The fact 
that we identified common pathways in different APAs sug-
gests that such pathways are particularly important in APA 
pathophysiology. However, additional studies including more 
patients are necessary to fully characterize APA-associated 
changes, especially at the phosphoproteome level. We have 
observed clustering of KCNJ5mut APA samples in 2 inde-
pendent bioinformatic analyses, indicating a distinct protein 
expression pattern associated with the mutated KCNJ5 chan-
nel. Unfortunately, the low number of samples precluded a 
valid analysis of pathways deregulated specifically in re-
sponse to the KCNJ5 mutation. In the same analyses, we also 
observed clustering of the control samples corresponding to 
the KCNJ5mut APAs. While paracrine/systemic factors from 
the APAs are one potential reason for the observed clustering, 
environmental factors such as salt intake, age, different zonal 
composition, and background genetic factors may also play 
a role. Additional studies are necessary to correlate genotype 
with phenotype in APAs.
Perspectives
This first deep quantitative (phospho)proteomic study of 
APAs has shown that increased steroid hormone production 
in APA is accompanied by increased expression of steroido-
genic enzymes and of the lipoprotein receptor LSR. It has 
demonstrated that the steroidogenic enzymes are phosphory-
lated, raising the possibility that these enzymes are regulated 
by protein kinases. Furthermore, our proteomic analysis has 
revealed that APAs have altered extracellular matrix composi-
tion, increased protein N-glycosylation and possibly reduced 
GABAergic signaling. Understanding the physiological and 
clinical relevance of these findings may translate into novel 
APA/PA therapeutic strategies.
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What Is New?
•	Aldosterone-producing adenomas (APAs) increase steroidogenic output 
by upregulating steroidogenic enzymes (HSD3B2, CYP21A2, CYP11B2) 
and a receptor involved cholesterol uptake (LSR).
•	 HSD3B2 and CYP21A2 are phosphorylated, raising a possibility that activity 
of steroidogenic enzymes is commonly regulated by protein kinases.
•	APAs have a distinct ECM (extracellular matrix) composition compared 
with the adjacent adrenal cortex, which affects ECM-cell surface 
interactions and actin cytoskeleton rearrangements.
•	RHOC, a GTPase controlling reorganization of actin cytoskeleton in re-
sponse to extracellular stimuli, is upregulated in adenomas and can in-
fluence expression of aldosterone synthase CYP11B2 in vitro.
•	APAs display higher levels of proteins involved in N-glycosylation and 
of enzymes controlling GABA degradation, suggesting that tumor devel-
opment might be associated with increased protein glycosylation and 
decreased inhibitory GABAergic signaling.
What Is Relevant?
•	Our study broadens the knowledge on APA pathophysiology and provides 
a rich resource for the future research on the molecular mechanisms and 
clinical management of primary aldosteronism.
Summary
We describe the first deep quantitative (phospho)proteome of 
aldosterone-producing adenomas. We identify novel proteins and 
pathways possibly involved in APA pathophysiology. Understanding 
clinical implications of these observations could lead to the devel-
opment of novel treatments for primary aldosteronism.
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